SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced two poster presentations featuring BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction, at the San Antonio Breast Cancer Symposium (SABCS) being held December 9-12, 2025, in San Antonio, Texas. The abstracts released today can be found on the SA ...

Core Insights - BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies and has announced poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [1][2] Company Overview - BBOT is advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, aiming to improve outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors [3] Conference Presentations - The company will present BBO-11818, an orally bioavailable, highly potent and selective non-covalent pan-KRAS inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models during a poster session on October 23 [4] - Another presentation will feature BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction, which inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia, scheduled for October 25 [4]

Links for live webcasts and replays, if available, will be available in the on the "Investors" page of the BBOT website. Replays will be available on the website for at least 90 days following the event. SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS- pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in S ...

Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed concurrent $261 million private investment in public equity (“PIPE”), led by Cormorant Combining approximately $120 million from the former Helix II trust account (reflecting a final redemption rate of approximately 39% which is the second lowest redemption rate for a biotech de-SPAC transaction since 2022) with the ...